Sildenafil Tablet, Film Coated
Product Images NDC 68071-4674

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 68071-4674). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 4674 3

Sildenafil 50 mg film-coated tablets label from NuCare Pharmaceuticals, Inc. The label shows the product name, strength, dosage form, and quantity (#30 tablets). It includes manufacturer details, NDC numbers, lot and serial numbers, and storage instructions to keep at 68-77°F. The label also contains warnings and patient instructions.*

FDA Label Image

Camberlogo1 (Camberlogo1)

FDA Label Image

Camberlogo2 (Camberlogo2)

FDA Label Image

Sildenafilfigure7 (Sildenafilfigure7)

A bar chart showing the percentage of patients reporting improvement across four treatment groups: Placebo (24%), Sildenafil Citrate Tablets 25 mg (63%), 50 mg (74%), and 100 mg (82%). The chart compares efficacy by dosage group with patient counts provided (n=463 to n=380).*

FDA Label Image

Sildenafilfigure1 (Sildenafilfigure1)

A line graph comparing systolic blood pressure changes (mmHg) over 24 hours post dose between Sildenafil 100 mg and placebo. The x-axis is labeled with time in hours post dose, and the y-axis shows systolic blood pressure values ranging from -25 to 15 mmHg. Data points for both Sildenafil and placebo groups are plotted and connected by lines.*

FDA Label Image

Sildenafilfigure2 (Sildenafilfigure2)

A line graph comparing the change in blood pressure (mmHg) over time (hours) for subjects administered Sildenafil 25 mg versus placebo. The x-axis represents time in hours, and the y-axis shows the change in blood pressure. Two lines represent the treatment groups, illustrating the blood pressure variation during the study period.*

FDA Label Image

Sildenafilfigure3 (Sildenafilfigure3)

A line graph showing change in blood pressure over time in hours postdose. Two lines represent the effects of Doxazosin with Placebo and Doxazosin with Sildenafil 50 mg. The y-axis indicates change in blood pressure (mmHg), and the x-axis shows time postdose (hours). Data points are connected by lines with markers for each treatment group.*

FDA Label Image

Sildenafilfigure4 (Sildenafilfigure4)

A line graph comparing the effects of Doxazosin combined with Sildenafil 100 mg versus Doxazosin combined with Placebo over 8 hours. The y-axis measures an unspecified variable in mmHg, displaying values ranging from -50 to 40, while the x-axis represents time after dosing in hours.*

FDA Label Image

Sildenafilfigure5 (Sildenafilfigure5)

A pharmacokinetic graph showing plasma concentration (ng/mL) of a treatment labeled 'Commercial Tablet' over time (hours) post-dose, from 0 to 24 hours. The concentration peaks early, then gradually decreases over the 24-hour period.*

FDA Label Image

Sildenafilfigure6a (Sildenafilfigure6a)

A bar chart depicting the percentage of patients at endpoint across different baseline scores ranging from 0 to 5. Multiple bars of varying heights represent different categories or groups, with a legend indicating six separate series labeled 0 through 5.*

FDA Label Image

Sildenafilfigure6b (Sildenafilfigure6b)

A bar chart displaying the distribution of baseline scores on the x-axis compared to the percentage of patients at the endpoint on the y-axis, with multiple bars per baseline score category distinguished by different shading patterns labeled 00 through 05. The chart illustrates patient response variability related to baseline scores.*

FDA Label Image

Sildenafilheterologo1 (Sildenafilheterologo1)

FDA Label Image

Sildenafilheterologo2 (Sildenafilheterologo2)

FDA Label Image

Sildenafilstructure (Sildenafilstructure)

Chemical structure diagram of sildenafil and its associated counterion, representing the active ingredient sildenafil from NuCare Pharmaceuticals, Inc. This depiction shows the molecular arrangement of atoms including nitrogen-containing rings and functional groups characteristic of sildenafil.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.